The company and one of its subsidiaries would allegedly confuse clinicians and have them bill government programs for cardiac monitoring services that were more expensive than what they needed. This settlement resolves those allegations. 

“We identified a problem in cardiology,” one cardiologist explained. “Heart imaging has made remarkable progress in recent decades, but the electrics of the heart have eluded us."

Ziad Ali, MD, detailed two studies he presented on coronary intravascular lithotripsy at TCT 2023 in San Francisco.

Asian patients are rarely represented in large TAVR trials, the authors wrote, so they focused on nearly 1,200 patients from South Korea to provide a fresh perspective. 

A hybrid approach may increase the risk of certain adverse events, according to a new meta-analysis focused on long-term outcomes. 

Abbott's HeartMate 3 LVAD is the only FDA-approved device of its kind currently available in the United States. Should reports of adverse events worry cardiologists? Or are they to be expected when treating such a vulnerable patient population?

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

AI-based prediction models have shown significant promise, but many are still flawed in a way that limits their value.